Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00220194
Status:
COMPLETED
Last Update Posted:
2016-10-14
First Post:
2005-09-17
Brief Title:
A Six-Month Open-Label Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 225 Mg And Eligard 225 Mg Or Zoladex 108 Mg And Eligard 225 Mg In Patients With Advanced Prostate Cancer
Sponsor:
San Bernardino Urological Associates Medical Group Inc
Organization:
San Bernardino Urological Associates Medical Group Inc
Organization Data
Organization:
San Bernardino Urological Associates Medical Group Inc
Class:
OTHER
Study ID:
SBU001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
San Bernardino Urological Associates Medical Group Inc
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None